Epizyme (EPZM) Misses Q2 EPS by 9c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020 6:30 AM ESTTAZVERIK (tazemetostat) Commercial Launch Underway for Epithelioid Sarcoma
TAZVERIK sNDA for Follicular Lymphoma Accepted for Filing by FDA with Priority Review; PDUFA Target Action Date of June 18, 2020
Expanding Future TAZVERIK Value through Clinical Development into New Combinations and Indications
Conference Call to be Held Today, Feb. 24 at 8:30 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS... More



